中證監:推動完善代表人訴訟制度機制
中國證監會發言人表示,康美藥業連續3年實施財務造假,涉案金額巨大,持續時間長,性質特別嚴重,社會影響惡劣,嚴重損害了投資者的合法權益。此次法院依法對康美藥業案作出一審判決,示範意義重大。證監會對此表示支持,並將依法監督投資者保護機構,配合人民法院做好後續相關工作。下一步,證監會將推動完善代表人訴訟制度機制,依法推進特別代表人訴訟常態化開展。
廣州中院對康美藥業(600518.SH)特別代表人訴訟案依法作出一審判決。法院綜合考慮案件基本事實、相關被告在虛假陳述行爲中的主觀過錯等因素,判決康美藥業承擔24.59億元人民幣的賠償責任;公司實控人馬興田夫婦及邱錫偉等4名原高管人員,組織策劃實施財務造假,屬故意行爲,承擔100%的連帶賠償責任;另有13名高管人員按過錯程度分別承擔連帶賠償責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.